Enzastaurin in Treating Patients With Recurrent Gliomas
|Phase I||Treatment||Closed||18 and over||NCI||NCI-05-C-0136|
Special Category: NCI Web site featured trial
- Determine the maximum tolerated dose of enzastaurin in patients with recurrent gliomas.
- Compare twice daily dosing of this drug with once daily dosing, in terms of systemic exposure to this drug and its metabolites, in these patients.
- Correlate, preliminarily, protein kinase C-β activity (specifically GSK3-β activation) in peripheral blood mononuclear cells with clinical outcome in patients treated with this drug.
- Determine, preliminarily, the antitumor activity of this drug in these patients.
- Histologically confirmed malignant glioma, including any of the following:
- Glioblastoma multiforme
- Anaplastic astrocytoma
- Anaplastic oligodendroglioma
- Anaplastic mixed oligoastrocytoma
- Malignant glioma not otherwise specified
- Primitive neuroectodermal tumors of the CNS
- Progressive low-grade gliomas
- Radiographically diagnosed brain stem gliomas that are refractory to standard treatment
- Recurrent disease
- Must have failed prior radiotherapy
- Unequivocal evidence of tumor progression by MRI or CT scan while on a steroid dosage that has been stable for ≥ 5 days
- At least 1 week since prior interferon or thalidomide
- No concurrent immunotherapy
- At least 2 weeks since prior vincristine
- At least 6 weeks since prior nitrosoureas
- At least 3 weeks since prior procarbazine
- No concurrent standard or anticancer chemotherapy
- See Disease Characteristics
- At least 1 week since prior tamoxifen
- See Disease Characteristics
- At least 4 weeks since prior and no concurrent radiotherapy
- Prior surgical resection of recurrent or progressive tumor allowed provided patient has recovered
- Residual disease after prior resection of tumor is not required
- Recovered from prior therapy
- At least 2 weeks since prior noncytotoxic investigational agents
- At least 4 weeks since prior cytotoxic therapy
- At least 1 week since other prior noncytotoxic agents (e.g., isotretinoin) except radiosensitizers
- At least 2 weeks since prior enzyme-inducing antiepileptic drugs (stratum 1)
- No other concurrent investigational agents
- 18 and over
- Karnofsky 60-100%
- More than 8 weeks
- WBC ≥ 3,000/mm3
- Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Hemoglobin ≥ 10 g/dL*
[Note: *Transfusion allowed]
- SGOT ≤ 2 times upper limit of normal (ULN)
- Bilirubin ≤ 2 times ULN
- No significant hepatic disease
- No significant active cardiac disease
- No QTc with Bazett's correction that is unmeasurable OR QTc ≥ 460 msec by ECG
- Patients with a QTc ≥ 460 msec by ECG allowed provided repeat ECG is performed ≥ 24 hours later and the average QTc from both ECGs is < 460 msec
- No clinically significant arrhythmia (i.e., multifocal premature ventricular contraction, bigeminy, trigeminy, ventricular tachycardia, or bradycardia) by ECG that is symptomatic or requires treatment
- No asymptomatic sustained ventricular tachycardia
- No ECG suggestive of past or present cardiac ischemia unless patient undergoes appropriate cardiac testing (i.e., echocardiogram and stress test) and the results are negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3-6 months after study participation
- Must be able to swallow study drug
- No significant uncontrolled medical illness that would preclude study participation
- No other active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No active infection requiring IV antibiotics
- No disease that would obscure toxicity or dangerously alter drug metabolism
Approximately 42 patients (approximately 24 in stratum 1 and 12 in stratum 2) will be accrued for this study.
This is a dose-escalation study. Patients are stratified according to concurrent enzyme-inducing antiepileptic drug (EIAED) (e.g., phenytoin, carbamazepine, or trileptal) use (yes vs no).
- Stratum 1 (no concurrent EIAEDs): Patients receive oral enzastaurin once daily in weeks 1-3 and then twice daily in weeks 4-6 OR twice daily in weeks 1-3 and then once daily in weeks 4-6 (course 1). Beginning in course 2, patients receive oral enzastaurin twice daily in weeks 1-6. Treatment repeats every 6 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity. After 9 courses of therapy, patients may receive additional courses at the investigator's discretion.
Cohorts of 12 patients receive escalating doses of enzastaurin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 4 of 12 patients experience dose-limiting toxicity.
- Stratum 2 (receiving concurrent EIAEDs): Patients receive oral enzastaurin as in stratum 1.
Cohorts of 6 patients receive escalating doses of enzastaurin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
After completion of study treatment, patients are followed within 2 weeks.Published Results
Kreisl TN, Kim L, Moore K, et al.: A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 15 (10): 3617-23, 2009.[PUBMED Abstract]
Trial Lead Organizations
NCI - Center for Cancer Research
|Howard Fine, MD, Principal investigator|
|Official Title||A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas|
|Trial Start Date||2005-05-24|
|Registered in ClinicalTrials.gov||NCT00112788|
|Date Submitted to PDQ||2005-04-12|
|Information Last Verified||2007-10-04|
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.